Rallybio Corp
RLYB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RLYB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RLYB
Rallybio Corp (RLYB) is a clinical-stage biotechnology company focused on developing therapies for rare diseases, with a lead program in fetal and neonatal alloimmune thrombocytopenia (FNAIT) and a pipeline including complement inhibitor RLYB116.
Key risk: No approved products or revenue
BioSniper Score
Based on 5 of 6 signals
Market Cap
$89.3M
Cash Runway
—
Lead Asset
rev102 (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 6 pipeline candidates · 3 clinical trials for Rallybio Corp.
Rallybio Corp (RLYB) is a clinical-stage biotechnology company focused on developing therapies for rare diseases, with a lead program in fetal and neonatal alloimmune thrombocytopenia (FNAIT) and a pipeline including complement inhibitor RLYB116.
- Rallybio is advancing a Phase 2 clinical trial for RLYB212, its lead product candidate for FNAIT, and conducting a natural history study to support regulatory submissions [sec_mda · as of 2025-03-13].
- The company reported cash and equivalents of $92.8M as of June 30, 2026, with no revenue and a net income of $43.7M for the period [sec].
- Rallybio plans to expand R&D activities, including future clinical trials for RLYB116 and other candidates, and expects expenses to increase substantially as it advances its pipeline [sec_mda · as of 2025-11-06].
- The company has no ongoing material financing commitments such as lines of credit or guarantees that are expected to affect liquidity over the next five years [sec_mda · as of 2025-03-13].
What works
- Rallybio has a strong cash position of $92.8M as of June 30, 2026, providing a runway to advance its pipeline without immediate financing pressure [sec].
- The company reported a net income of $43.7M for the period ending June 30, 2026, indicating a positive financial result in that quarter [sec].
- Rallybio is advancing a Phase 2 trial for RLYB212 in FNAIT, a rare disease with high unmet need, supported by a natural history study [sec_mda · as of 2025-03-13].
What to weigh
- Rallybio has no approved products or revenue, and its future success depends on costly clinical development and regulatory approvals [sec_mda · as of 2025-11-06].
- The company will need to raise substantial additional capital to fund its operations, as clinical development costs are inherently unpredictable and can differ materially from expectations [sec_mda · as of 2025-11-06].
- Expenses are expected to increase substantially as Rallybio plans for future trials, regulatory submissions, and commercialization efforts, which could strain resources if capital is not secured [sec_mda · as of 2025-11-06].
From the filings
Quoted directly from source documents.
Rallybio expects expenses to increase as it advances its pipeline.
“Our expenses will increase substantially over time if and as we: ▪ plan for and conduct any future clinical trials for RLYB116 and any of our other product candidates; ▪ seek regulatory approvals for RLYB116 and any other product candidates”
SEC MD&A · November 6, 2025
Rallybio will need to raise additional capital.
“We will need to raise substantial additional capital in the future.”
SEC MD&A · November 6, 2025
Rallybio had $65.5 million in cash as of December 31, 2024.
“As of December 31, 2024, we had $65.5 million of cash, cash equivalents and marketable securities.”
SEC MD&A · March 13, 2025
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Rallybio has no products approved for commercial sale and has generated no revenue from product sales [sec_mda · as of 2025-11-06].
- Need for substantial additional capital — The company will need to raise substantial additional capital to fund operations, clinical trials, and regulatory activities [sec_mda · as of 2025-11-06].
- Unpredictable clinical development — Clinical development timelines, probability of success, and costs can differ materially from expectations [sec_mda · as of 2025-11-06].
- Increasing expenses — Expenses are expected to increase substantially as the company advances its pipeline and seeks regulatory approvals [sec_mda · as of 2025-11-06].
What to watch
- Progress of the Phase 2 clinical trial for RLYB212 in FNAIT and results from the natural history study [sec_mda · as of 2025-03-13].
- Initiation and outcomes of future clinical trials for RLYB116 and other pipeline candidates [sec_mda · as of 2025-11-06].
- Any capital-raising activities or partnerships to fund ongoing operations and development [sec_mda · as of 2025-11-06].
- Regulatory milestones, including submissions for RLYB212 and RLYB116 [sec_mda · as of 2025-03-13].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Rallybio Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Rallybio Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.04 · 2% dilution
Lead: Phase 2
6 candidates
No upcoming catalysts tracked
14 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
33
Total value held
$28.8M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 793,451 | $7.1M |
| viking global investors lp | 524,347 | $4.7M |
| balyasny asset management l.p. | 376,573 | $3.4M |
| laurion capital management lp | 302,756 | $2.7M |
| pivotal bioventure partners investment advisor llc | 300,579 | $2.7M |
| vanguard capital management llc | 224,080 | $2.0M |
| renaissance technologies llc | 156,527 | $1.4M |
| johnson & johnson | 152,901 | $1.4M |
| aju ib investment co., ltd. | 94,334 | $846K |
| mariner, llc | 50,566 | $454K |
Showing top 10 of 33 institutional holders of Rallybio Corp. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 35.8%
- Days to cover
- 23.9
- Shares short
- 1,572,902
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RLYB short interestGovernance
Frequently asked questions
What is the AI investment thesis for Rallybio Corp?
Rallybio Corp (RLYB) is a clinical-stage biotechnology company focused on developing therapies for rare diseases, with a lead program in fetal and neonatal alloimmune thrombocytopenia (FNAIT) and a pipeline including complement inhibitor RLYB116.
What is Rallybio Corp's lead drug candidate?
Rallybio Corp's most advanced tracked candidate is rev102 (Preclinical) for Hypophosphatasia (HPP).
Who is the CEO of Rallybio Corp?
Dr. Stephen Uden M.D., MBBS is the chief executive officer of Rallybio Corp (RLYB).
Where is Rallybio Corp headquartered?
Rallybio Corp (RLYB) is headquartered in New Haven, CT, United States.
What therapeutic areas does Rallybio Corp focus on?
Rallybio Corp develops therapies across Oncology, Rare Disease, Immunology, Ophthalmology, Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.